Skip to main content

Table 1 Baseline characteristics of women in the Prospective Family Study Cohort by regular aspirin use

From: Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study

 

Prospective cohorta

Combined cohortb

Non-regular user

Regular user

Non-regular User N = 6636

Regular user

N = 4616

N = 990

N = 1597

Baseline characteristic

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Age, years

41.7 (12.7)

53.1 (11.7)

44.0 (12.9)

54.2 (11.5)

Race and ethnicity, No. (%)

 Non-Hispanic white

4269 (92.5)

888 (89.7)

5860 (88.3)

1366 (85.5)

 Other

274 (5.9)

94 (9.5)

694 (10.5)

223 (14.0)

 Missing

73 (1.6)

8 (0.8)

82 (1.2)

8 (0.5)

Cigarette smoking, No. (%)

 Never

2688 (58.2)

575 (58.1)

3862 (58.2)

896 (56.1)

 Former

1088 (23.6)

267 (27.0)

1705 (25.7)

492 (30.8)

 Current

469 (10.2)

91 (9.2)

663 (10.0)

140 (8.8)

 Missing

371 (8.0)

57 (5.8)

406 (6.1)

69 (4.3)

Alcohol consumption, No. (%)

 Never

1852 (40.1)

532 (53.7)

2943 (44.4)

841 (52.7)

 Former

755 (16.4)

129 (13.0)

1062 (16.0)

220 (13.8)

 Current

1924 (41.7)

318 (32.1)

2514 (37.9)

513 (32.1)

 Missing

85 (1.8)

11 (1.1)

117 (1.8)

23 (1.4)

Hormone therapy use, No. (%)

 Never

3717 (80.5)

542 (54.8)

5255 (79.2)

895 (56.0)

 Former

409 (8.9)

191 (19.3)

758 (11.4)

361 (22.6)

 Current

430 (9.3)

230 (23.2)

522 (7.9)

290 (18.2)

 Missing

60 (1.3)

27 (2.7)

101 (1.5)

51 (3.2)

Hormonal birth control use, No. (%)

 Never

635 (13.8)

253 (25.6)

1224 (18.4)

480 (30.1)

 Former

3043 (65.9)

659 (66.6)

4373 (65.9)

1015 (63.6)

 Current

900 (19.5)

59 (6.0)

973 (14.7)

69 (4.3)

 Missing

38 (0.8)

19 (1.9)

66 (1.0)

33 (2.1)

COX-2 inhibitors, No. (%)

 Non-regular user

4227 (91.6)

814 (82.2)

6140 (92.5)

1366 (85.5)

 Regular user

358 (7.8)

161 (16.3)

428 (6.5)

199 (12.5)

 Missing

31 (0.7)

15 (1.5)

68 (1.0)

32 (2.0)

Ibuprofen and other NSAIDsc, No. (%)

 Non-regular user

3911 (84.7)

714 (72.1)

5512 (83.1)

1139 (71.3)

 Regular user

682 (14.8)

258 (26.1)

1063 (16.0)

426 (26.7)

 Missing

23 (0.5)

18 (1.8)

61 (0.9)

32 (2.0)

Acetaminophen, No. (%)

 Non-regular user

3859 (83.6)

740 (74.8)

5597 (84.3)

1214 (76.0)

 Regular user

737 (16.0)

238 (24.0)

985 (14.8)

361 (22.6)

 Missing

20 (0.4)

12 (1.2)

54 (0.8)

22 (1.4)

BOADICEA 1-year risk score, %

0.51 (0.71)

0.68 (0.85)

0.50 (0.72)

0.64 (0.83)

Mutation carrier status, No. (%)

 Non-carrierd

4070 (88.2)

915 (92.4)

5739 (86.5)

1440 (90.2)

 BRCA1 mutation carrier

292 (6.3)

37 (3.7)

500 (7.5)

84 (5.3)

 BRCA2 mutation carrier

254 (5.5)

38 (3.8)

397 (6.0)

73 (4.6)

  1. aIncludes women with no personal history of breast cancer when regular medication use was asked by questionnaire (N = 5606)
  2. bIncludes retrospective breast cancer cases (diagnosed prior to baseline and/or follow-up questionnaire) and prospective breast cancer cases (diagnosed after follow-up questionnaire) (N = 8233)
  3. cNon-steroidal anti-inflammatory drugs
  4. dIncludes true negatives and women who did not undergo genetic testing for BRCA1 and BRCA2